GENENTECH, BIOCINE GP120 HIV VACCINE PHASE II STUDIES SHOULD CONTINUE BUT PHASE III PREVENTIVE TRIALS SHOULD AWAIT MORE DATA -- NIAID AIDS ADVISORY CMTE.
Executive Summary
Phase II trials of Genentech's and Biocine's gp120 HIV vaccines should continue, but the data do not warrant a progression to large-scale Phase III trials, the National Institute of Allergy & Infectious Diseases AIDS Research Advisory Committee recommended at a June 17 meeting.